DXC
DXC Technology Company
DXC trails on the overall score without a compensating advantage in the available component scores.
NVDA
NVIDIA Corporation
NVDA has the edge over DXC overall, supported by stronger valuation and stronger fundamentals.
DXC Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Stable | |
| Stable | |
| Healthy |
DXC's balance sheet is currently healthy, and its revenue, profitability and cash flow are stable.
NVDA Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Strong | |
| Strong | |
| Strong |
NVDA's revenue, profitability, cash flow and balance sheet are all currently strong.
DXC PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 5.7x | $14.85 | — |
| Cheap | 6.9x | $4.77 | -68% |
| Fair | 12x | $8.59 | -42% |
| Current | 22x | $14.85 | — |
| Expensive | 47x | $32.15 | +117% |
Historical ranges are pointers, not guarantees.
DXC's PE is in its fair range at 22x. On analysts' estimates for next year's earnings, today's price would be 5.7x, in its cheap range.
NVDA PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $166 | — |
| Current | 21x | $166 | — |
| Cheap | 44x | $345 | +108% |
| Fair | 65x | $511 | +207% |
| Expensive | 93x | $734 | +342% |
Historical ranges are pointers, not guarantees.
NVDA has the edge over DXC in the historical PE scenario, which offers more potential upside but is not a forecast.
DXC Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Stable | |
| Stable | |
| Stable | |
| Limited | |
| Moderate |
Analysts expect DXC's earnings, revenue and profitability to hold roughly steady.
NVDA Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Weakening | |
| Broad | |
| Moderate |
Analysts expect strong earnings and revenue growth for NVDA, but weaker profitability.
DXC Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.58 | +274% |
| Q3 2026 | $0.69 | -66% |
| Q2 2026 | $0.74 | -64% |
| Q1 2026 | $0.10 | -95% |
| Q4 2025 | $2.32 | +$2.65 |
| Q3 2025 | $2.02 | +1088% |
| Q2 2025 | $2.05 | +377% |
| Q1 2025 | $2.10 | +357% |
| Q4 2024 | -$0.33 | +$1.48 |
DXC's earnings per share have fallen from their peak: $0.69 over the past year, against $3.03 in late 2022.
NVDA Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $13.77 | +74% |
| Q3 2026 | $7.91 | +125% |
| Q2 2026 | $6.53 | +111% |
| Q1 2026 | $4.90 | +67% |
| Q4 2025 | $4.03 | +59% |
| Q3 2025 | $3.51 | +65% |
| Q2 2025 | $3.10 | +81% |
| Q1 2025 | $2.94 | +147% |
| Q4 2024 | $2.54 | +234% |
NVDA has the edge over DXC on earnings, with more consistent year-over-year improvement.
DXC Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $3B | -4% |
| Q2 2026 | $3B | -5.1% |
| Q1 2026 | $3.1B | -1.2% |
| Q4 2025 | $3.2B | -1% |
| Q3 2025 | $3.2B | -2.5% |
| Q2 2025 | $3.2B | -2.4% |
| Q1 2025 | $3.2B | -6.4% |
| Q4 2024 | $3.2B | -5.1% |
DXC's revenue fell from its 2019 peak and has held roughly level since: $3B last quarter, down 4% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 6.2% | -1.9 points |
| Q2 2026 | 5% | -1.8 points |
| Q1 2026 | 7.6% | +0.3 points |
| Q4 2025 | 8.2% | -0.6 points |
| Q3 2025 | 8% | -0.6 points |
| Q2 2025 | 6.8% | 0 points |
| Q1 2025 | 7.3% | -1.1 points |
| Q4 2024 | 8.9% | +1.3 points |
DXC's operating margin was 6.2% last quarter, down 1.9 points from the same quarter a year ago, near the bottom of its range since 2019.
NVDA Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $96.2B | +106% |
| Q2 2026 | $81.6B | +85% |
| Q1 2026 | $68.1B | +73% |
| Q4 2025 | $57B | +62% |
| Q3 2025 | $46.7B | +56% |
| Q2 2025 | $44.1B | +69% |
| Q1 2025 | $39.3B | +78% |
| Q4 2024 | $35.1B | +94% |
NVDA has the edge over DXC on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 66% | +5.4 points |
| Q2 2026 | 66% | +17 points |
| Q1 2026 | 65% | +3.9 points |
| Q4 2025 | 63% | +0.8 points |
| Q3 2025 | 61% | -1.2 points |
| Q2 2025 | 49% | -16 points |
| Q1 2025 | 61% | -0.5 points |
| Q4 2024 | 62% | +4.9 points |
NVDA has the edge over DXC on profitability, with a higher operating margin.
DXC Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $143M | -61% |
| Q2 2026 | $359M | +151% |
| Q1 2026 | $169M | -29% |
| Q4 2025 | $359M | -37% |
| Q3 2025 | $365M | +137% |
| Q2 2025 | $143M | -25% |
| Q1 2025 | $238M | -1.7% |
| Q4 2024 | $568M | -15% |
DXC generated $1B in free cash flow over the past year, down 22% from the year before.
NVDA Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $21.4B | +59% |
| Q2 2026 | $48.6B | +86% |
| Q1 2026 | $34.9B | +124% |
| Q4 2025 | $22.1B | +32% |
| Q3 2025 | $13.5B | -0.3% |
| Q2 2025 | $26.2B | +75% |
| Q1 2025 | $15.6B | +38% |
| Q3 2024 | $13.5B | +113% |
NVDA has the edge over DXC on cash flow, with more consistent year-over-year improvement.
DXC Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -2.6% | -4.3M shares |
| 1 year | -9.6% | -17.2M shares |
| 3 years | -20% | -41.1M shares |
| 5 years | -36% | -90.4M shares |
| Available history | -37% | -94.1M shares |
DXC has the edge over NVDA on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $61M |
| Q2 2026 | $71M |
| Q1 2026 | $61M |
| Q4 2025 | $64M |
| Q3 2025 | $76M |
| Q2 2025 | $48M |
| Q1 2025 | — |
| Q4 2024 | $12M |
DXC spent $257M buying back its own shares over the past year, up 89% from the year before.
NVDA Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.4% | -106M shares |
| 1 year | -1% | -247M shares |
| 3 years | -2.8% | -705M shares |
| 5 years | -4.1% | -1B shares |
| Available history | -1.8% | -435M shares |
NVDA has 24.3B diluted shares, down 1% from a year ago, with $55.3B in buybacks over the past year.
| Quarter | Spent |
|---|---|
| Q3 2026 | $19.7B |
| Q2 2026 | $19.3B |
| Q1 2026 | $3.8B |
| Q4 2025 | $12.5B |
| Q3 2025 | $9.7B |
| Q2 2025 | $14.1B |
| Q1 2025 | $7.8B |
| Q4 2024 | $11B |
NVDA spent $55.3B buying back its own shares over the past year, up 30% from the year before.
DXC Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 0.7x | Very low |
| Q2 2026 | 0.8x | Very low |
| Q1 2026 | 0.9x | Very low |
| Q4 2025 | 0.9x | Very low |
| Q3 2025 | 0.9x | Very low |
| Q2 2025 | 1.0x | Very low |
| Q1 2025 | 0.9x | Very low |
| Q4 2024 | 0.9x | Very low |
DXC's net debt is less than a year of its operating earnings (EBITDA).
NVDA Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 0.1x | Very low |
| Q2 2026 | -0.0x | Net Cash |
| Q1 2026 | -0.0x | Net Cash |
| Q4 2025 | -0.0x | Net Cash |
| Q3 2025 | -0.0x | Net Cash |
| Q2 2025 | -0.1x | Net Cash |
| Q1 2025 | -0.0x | Very low |
| Q4 2024 | -0.0x | Net Cash |
NVDA has the edge over DXC on leverage, with a lower net debt burden relative to earnings.
DXC Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 64.6 | Neutral |
| Stochastic | 76.3 | Neutral |
DXC's weekly RSI is 65 (neutral) and its Stochastic is 76 (neutral).
NVDA Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 33.4 | Neutral |
| Stochastic | 18.1 | Oversold |
NVDA's weekly RSI is 33 (neutral) and its Stochastic is 18 (oversold).
DXC PE vs Technology Sector
| Metric | DXC | Sector median | Relative |
|---|---|---|---|
| PE | 22x | 28x | 23% below |
| PE % | 63 | 35 | 28 pts above |
DXC is trading at 22x earnings, a 23% discount to the Technology sector's median of 28x.
NVDA PE vs Technology Sector
| Metric | NVDA | Sector median | Relative |
|---|---|---|---|
| PE | 21x | 28x | 25% below |
| PE % | 0 | 35 | 35 pts below |
NVDA has the edge over DXC on valuation relative to its sector.
DXC Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $13.6 | 9.4% above |
| 20 week MA | $11.8 | 26% above |
| 50 week MA | $12.1 | 22% above |
| 100 week MA | $14.0 | 6.1% above |
| 200 week MA | $18.1 | 18% below |
DXC has the edge over NVDA on trend strength, trading above more of its moving averages.
NVDA Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $208.9 | 20% below |
| 20 week MA | $212.0 | 22% below |
| 50 week MA | $199.9 | 17% below |
| 100 week MA | $175.1 | 5.1% below |
| 200 week MA | $123.6 | 34% above |
NVDA has fallen below most of its moving averages, though it's still 34% above its 200-week average.
DXC Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $36.7 | $22.9 | -38% |
| 2021 | $22.9 | $32.6 | +42% |
| 2022 | $32.6 | $26.5 | -19% |
| 2023 | $26.5 | $22.9 | -14% |
| 2024 | $22.9 | $20.2 | -12% |
| 2025 | $20.2 | $15.1 | -25% |
| 2026 YTD | $15.1 | $14.9 | -1.7% |
DXC has the edge over NVDA on returns for 2026, with the stronger performance.
NVDA Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $5.92 | $13.0 | +119% |
| 2021 | $13.0 | $29.6 | +128% |
| 2022 | $29.6 | $15.2 | -49% |
| 2023 | $15.2 | $49.5 | +226% |
| 2024 | $49.5 | $137.0 | +177% |
| 2025 | $137.0 | $190.5 | +39% |
| 2026 YTD | $190.5 | $166.2 | -13% |
NVDA's yearly returns have swung widely, from +226% in 2023 to −49% in 2022. It's down 13% so far in 2026.